News & Press

Filter by year:

GeNeuro Reports 2018 Half-Year Results and Provides Corporate Update

 

Robust cash position of €17.3 million as of June 30, 2018

All clinical and research activities funded through 3Q2019

GeNeuro Reports 2018 Half-Year Results and Provides Corporate Update

 

Robust cash position of €17.3 million as of June 30, 2018

All clinical and research activities funded through 3Q2019

GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier

Based on R&D strategic reasons, Servier declines option to license and to further fund the development of GNbAC1 in MS

Following positive Phase IIb 12-month results, GeNeuro will pursue further development and worldwide partnering options

GeNeuro: financial information and business update for the second quarter 2018

GeNeuro today issued a business update and reported on its cash position and 2018 first-quarter revenues.

A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti‐HERV‐W‐Env monoclonal antibody

François Curtin MD, Corinne Bernard PhD, Sandrine Levet PhD, Hervé Perron PhD, Hervé Porchet MD, Julie Médina PhD, Sam Malpass MSc, David Lloyd PhD, Richard Simpson DM

 

HERV-W-Env involvement in human T1D pathogenesis

S. Levet, J. Joanou, N. Queruel, J.Pierquin & H. Perron

 

GeNeuro Presents New Data Highlighting Role of Human Endogenous Retroviruses in Type 1 Diabetes at American Diabetes Association’s (ADA) 78th Scientific Sessions

Geneva, Switzerland, June 25, 2018 – 7:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclerosis (MS) and type 1 diabetes (T1D), today announced that new data from mouse models confirm the involvement of a pathogenic protein encoded by a member of the human endogenous retroviruses (HERV-W) family, pHERV-W Env, in human T1D pathogenesis. Data were presented at the American Diabetes Association 78th Scientific Session, being held June 22-26, 2018 in Orlando, Florida.

Le Revenu TV - «Servier pourrait licencier un produit de Geneuro»

Le PDG de la biotech franco-suisse a expliqué au Revenu TV pourquoi les résultats mitigés de son GNbAC1 dans une forme de sclérose en plaques n'empêchent pas forcément la poursuite de son développement clinique. Il est aussi revenu sur le parcours boursier de la société, très chahuté en 2017.

 

GeNeuro: financial information and business update for the first quarter 2018

GeNeuro today issued a business update and reported on its cash position and 2018 first-quarter revenues.

GeNeuro Reports 2017 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, 3 April 2018 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis (MS) and Type-1 Diabetes (T1D), today reported its full-year results for the year ended December 31, 2017 and provided a corporate update.


Start Page      Previous Page      Results 11-20 of 24      Next Page      Last Page